Matches in Nanopublications for { ?s ?p ?o <http://www.tkuhn.ch/bel2nanopub/RAUnatTAx72bZIAiovFmF7SSrKuiJ9NThgm9Hb9Udz2ik#provenance>. }
Showing items 1 to 11 of
11
with 100 items per page.
- _5 label "Selventa" provenance.
- large_corpus.bel rights "Copyright (c) 2011-2012, Selventa. All rights reserved." provenance.
- _4 value "IL-6 treatment led to activation of the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3'-kinase (PI3K) pathways. Inhibition of MAPK or PI3K activity reversed IL-6- and oncostatin M-stimulated migration. For transient transfections, plasmids were introduced into the cells using Superfect transfection reagent (Qiagen). A HA-tagged MAPK (Erk2) construct (kindly provided by M. El-Shemerly and Y. Nagamine; Friedrich Miescher Institute, Basel, Switzerland) was cotransfected with a DN EGF receptor construct lacking 533 COOH-terminal amino acids MAPK kinase inhibitors PD98059 (20 uM; New England Biolabs) or UO126 (50 uM; Promega, Madison, WI PD98059, which is known to specifically inhibit the ERK-activating kinase MEK1, has been widely used to assess the effects of dampening ERK activation. MEK inhibitor UO126 (Promega, MEK Inhibitor U0126 is a chemically synthesized organic compound that inhibits activation of MAPK (ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK 1/2)." provenance.
- _4 wasQuotedFrom 11196191 provenance.
- assertion hadPrimarySource 11196191 provenance.
- large_corpus.bel title "BEL Framework Large Corpus Document" provenance.
- large_corpus.bel description "Approximately 61,000 statements." provenance.
- assertion wasDerivedFrom large_corpus.bel provenance.
- assertion wasDerivedFrom _4 provenance.
- large_corpus.bel authoredBy _5 provenance.
- large_corpus.bel version "20131211" provenance.